Key Highlights
● Third-quarter revenue was $1,878 million, up 8.1% as reported.
● Non-GAAP earnings per share were $1.62, up from $1.37.
● Tariff refunds added about $0.06 per share to non-GAAP earnings.
● Full-year non-GAAP EPS guidance is $6.18 to $6.21.
Agilent Technologies, Inc. (NYSE:A), which trades on the New York Stock Exchange under the ticker A, published its results for the third quarter of fiscal 2026 on 26 August 2026. The quarter ended on 31 July 2026. Revenue reached $1,878 million, compared with $1,738 million a year earlier, an increase of 8.1 per cent as reported and 7.3 per cent on a core basis, which strips out currency effects and the impact of recent acquisitions and disposals.
Profitability improved more quickly than sales. GAAP net income was $362 million, or $1.28 per diluted share, against $336 million and $1.18 in the prior-year quarter. On a non-GAAP basis, which management uses to exclude items such as amortisation and restructuring costs, net income was $459 million and earnings per share were $1.62, up from $1.37. The GAAP operating margin was 23.6 per cent, while the non-GAAP margin was 28.3 per cent.
Tariff Refunds Flatter the Comparison
Agilent said the non-GAAP result included a $17 million benefit from tariff refunds, worth about $0.06 per share and roughly 110 basis points of operating margin. Those refunds are not expected to recur in the fourth-quarter guidance.
Segment Picture
The Life Sciences and Diagnostics Markets Group generated $746 million of revenue, up 11 per cent as reported and 10 per cent on a core basis, with an operating margin of 23.5 per cent. The Agilent CrossLab Group, which covers services and consumables, produced $786 million, up 6 per cent reported and 5 per cent core, at a 34.3 per cent margin. The Applied Markets Group delivered $346 million, up 7 per cent on both measures, with a 24.9 per cent margin.
Guidance for the Fourth Quarter and Full Year
Management raised its guidance. For the full fiscal year ending 31 October 2026, Agilent expects revenue of $7.49 billion to $7.51 billion and non-GAAP earnings per share of $6.18 to $6.21. The earnings range moved up by about $0.15 at the midpoint and includes the $0.06 refund benefit. For the fourth quarter, the company guided to revenue of $1.98 billion to $2.00 billion and non-GAAP earnings per share of $1.71 to $1.74. Core revenue growth for the year is guided at 5.8 to 6.0 per cent.
Balance Sheet and Capital Deployment
The nine-month cash flow statement shows roughly $950 million paid for acquisitions of businesses and intangible assets, while goodwill rose to $5,030 million from $4,473 million at 31 October 2025. The release does not name the transactions involved. Long-term debt increased to $3,645 million, including $600 million of new borrowing during the period, and cash stood at $1,758 million. Agilent also returned capital, paying $216 million in dividends and repurchasing $295 million of shares across the nine months.
For the nine months, revenue was $5,511 million, GAAP earnings per share were $3.55 and non-GAAP earnings per share were $4.48.
Lab Spending, Currency and Trade Policy Decide Whether Agilent's Raise Holds
The result matters because laboratory instrument makers are often treated as a gauge of pharmaceutical, chemical and academic spending. Agilent's chief executive, Padraig McDonnell, attributed the quarter to the company's strategy and said Agilent aims to outperform its end markets. Whether that holds depends on customer budgets, currency movements and trade policy, all of which sit outside management's control.
The next scheduled disclosure is the fourth-quarter and full-year report, for which the release gave no date.



_11_19_2026_18_10_09_455845.jpg)

_11_19_2026_18_15_38_890267.jpg)
Please wait processing your request...